Himalaya Nutravedics IPO GMP, Price Band, Subscription Status, Allotment Date

Himalaya Nutravedics IPO is a SME issue open from 22–24 September. The company is raising ₹26 Cr at a price band of ₹100 to ₹106 per share. One lot is 1,200 shares.

Himalaya Nutravedics IPO GMP (grey market premium)

₹0

Implied listing gain: ₹106 (0.00%)

Subscription

1.64x

Times the issue was bid for

On the GMP figure: grey market premium is quoted by informal dealers. No exchange publishes it, no regulator oversees it, and it is not a forecast of the listing price. Issues quoting a strong premium have listed below their issue price. Weigh the financials and the risk factors in the RHP well above this number.

Himalaya Nutravedics IPO Review & Analysis

Our reading of the numbers below — growth rates, margins, pricing and demand are calculated from the company's own filed figures, not copied from anywhere.

Minimum retail investment

₹1,27,200

1200 shares at the upper band of ₹106

Retail limit

1 lot

the most that fits under the ₹2 lakh retail cap

Funds blocked after close

~5 days

from the closing date to listing

Fresh issue share

96.2%

₹25 Cr of the ₹26 Cr issue

Revenue growth

+105.3%

31 Mar 2025 → 31 Mar 2026

Profit growth

+231.4%

PAT ₹2.23 Cr → ₹7.39 Cr

Net profit margin

17.1%

was 10.6% in 31 Mar 2025

Debt to equity

0.31

lower is safer

Return on equity

63.87%

ROE

Peer listing record

11 of 12 listed above issue price

median listing move +19.7%

Total subscription

1.64x

across all categories

Promoter holding

95.14% → 68.13%

diluted by 27 percentage points

Himalaya Nutravedics is an SME issue raising ₹26 Cr, offered in a band of ₹100–₹106 per share. At the upper end that is 10.6 times the ₹10 face value, so ₹96 of every share subscribed is share premium rather than capital. SME issues list on the BSE SME or NSE Emerge platform rather than the main board. They trade in fixed lots after listing, carry no retail-versus-HNI cut-off bidding, and are usually far less liquid, so exiting a position can take longer than on the main board.

A retail application for Himalaya Nutravedics needs one lot of 1200 shares, which works out to ₹1,27,200 at the upper band of ₹106. SME lots are deliberately sized above ₹1,00,000, so this is a far larger single commitment than a mainboard application and rules out most small investors. Retail applications are capped at ₹2,00,000, which here is 1 lot; bidding above that moves the application into the non-institutional category, and the large-HNI bucket begins at ₹10,00,000, or about 8 lots.

For Himalaya Nutravedics, bidding runs 22-24 Sep, allotment is finalised on 25 Sep 2026, the shares list on 29 Sep 2026. Applications that do not receive an allotment have their UPI mandate released around 1 day after the issue closes. Counting from the close of bidding, money stays blocked for roughly 5 days before listing decides what the holding is worth.

The issue is reserved 47.38% to qualified institutional buyers, 14.26% to non-institutional investors, 33.32% to retail. At 33.32%, the retail portion is on the narrower side, so retail allotment turns into a lottery quickly once the book fills. An oversubscribed retail portion is not allotted in proportion to the amount applied for: applications are reduced to single lots and drawn by lot, so several small applications from different PANs are more effective than one large one.

The issue splits into ₹25 Cr of fresh capital (96.2%) and ₹1 Cr as an offer for sale. The company keeps the fresh portion for the objects of the issue, while the rest is existing shareholders monetising their stake.

Revenue moved from ₹21 Cr in 31 Mar 2025 to ₹43.12 Cr in 31 Mar 2026 (+105.3%), while profit after tax went from ₹2.23 Cr to ₹7.39 Cr (+231.4%). Profit grew faster than revenue, which points to operating leverage or a better cost mix rather than growth bought purely through volume.

Recently listed companies in the same space trade at a median price-to-earnings ratio of about 20. Comparing that with the multiple implied by this issue's ₹100–₹106 band is a more useful test of pricing than looking at the grey market premium alone.

With the retail portion subscribed 2.56 times, roughly one in 3 single-lot applications can expect an allotment once the draw is made. Applying for more lots does not improve those odds in an oversubscribed retail book — every application is cut back to one lot before the lottery — so the practical lever is the number of distinct PANs applying, not the size of any one bid.

Kfin Technologies Ltd. is the registrar for this issue, which means the allotment status for Himalaya Nutravedics is published on their portal from 25 Sep 2026. A PAN, application number or demat client ID is enough to look it up; the credited shares also appear in the demat account itself a day or so before listing.

What looks good

  • Profit is growing faster than revenue, suggesting improving operating efficiency.
  • A debt-to-equity ratio of 0.31 points to a conservatively funded balance sheet.
  • Return on equity of 63.87% is strong for the sector.

What to watch

  • There is no grey market premium on this issue at present, which points to muted listing-day expectations.

The figures above are worked out from the issue's own filed numbers and are for information only. They are not investment advice — read the RHP before you apply.

IPO Date22–24 September
Face Value₹10 Per Share
Price Range₹100 to ₹106
Issue Size₹26 Cr
Lot Size1,200 Shares
Allotment Date25 Sep 2026
Listing Date29 Sep 2026
RegistrarKfin Technologies Ltd.

Quota Allocation

CategoryAllocation
Retail Investors33.32%
QIB (Qualified Institutional Buyers)47.38%
HNI (High Net Worth Individuals)14.26%

Subscription Status (Category-wise)

Investor CategorySubscription (times)
Qualified Institutional1.00x
Non Institutional3.58x
Retail Individual2.56x
Total1.64x

IPO Details

Total Issue Size24,99,600 shares (agg. up to ₹26 Cr)
Reserved for Market Maker1,26,000 shares (agg. up to ₹1 Cr)Allwin Securities Ltd.
Fresh Issue (Ex Market Maker)23,73,600 shares (agg. up to ₹25 Cr)
Net Offered to Public23,73,600 shares (agg. up to ₹25 Cr)
Share Holding Pre Issue63,06,720 shares
Share Holding Post Issue88,06,320 shares
BSE Script Code544943
ISININE1OTR01013

IPO Timetable

IPO OpenTue, Sep 22, 2026
IPO CloseThu, Sep 24, 2026
AllotmentFri, Sep 25, 2026
RefundMon, Sep 28, 2026
Credit of SharesMon, Sep 28, 2026
ListingTue, Sep 29, 2026

Issue Reservation

Investor CategoryShares% of Net Issue% of Total Issue
QIB11,84,40049.90%47.38%
− Anchor Investor7,10,40028.42%
− QIB (Ex. Anchor)4,74,00018.96%
NII (HNI)3,56,40015.02%14.26%
− bNII > ₹10L2,37,6009.51%
− sNII < ₹10L1,18,8004.75%
Retail8,32,80035.09%33.32%
Firm Reservations
Market Maker1,26,0005.04%
Total24,99,600100.00%100.00%

IPO Lot Size

ApplicationLotsSharesAmount
Individual investors (IND) (Min)22400₹2,54,400
Individual investors (IND) (Max)22400₹2,54,400
S-HNI (Min)33600₹3,81,600
S-HNI (Max)78400₹8,90,400
B-HNI (Min)89600₹10,17,600

IPO Anchor Investors

Bid DateMon, Sep 21, 2026
Shares Offered7,10,400
Anchor Portion (₹ Cr.)7.53
Anchor lock-in period end date for 50% shares (30 Days)Sat, Oct 24, 2026
Anchor lock-in period end date for remaining shares (90 Days)Wed, Dec 23, 2026

Company Financials (Restated Consolidated)

Period Ended31 Mar 202631 Mar 202531 Mar 2024
Assets24.4210.826.09
Total Income43.1221.0014.43
Profit After Tax7.392.230.43
EBITDA8.102.990.94
NET Worth16.386.751.34
Reserves and Surplus10.072.760.53
Total Borrowing5.131.763.24
Amount in ₹ Crore

Recently Listed IPOs in Pharmaceuticals

CompanyIssue TypeIssue SizeIssue PricePE RatioListing Day CloseListing Gain/Loss %LTP
Bio Medica Laboratories Ltd.SME₹52.43 Cr₹13913.03₹115.80-16.69%₹166.00
Goldline Pharmaceutical Ltd.SME₹11.61 Cr₹4310.47₹56.77+32.02%₹32.00
Speciality Medicines Ltd.SME₹29.14 Cr₹1249.27₹125.90+1.53%₹164.90
Accretion Nutraveda Ltd.SME₹24.77 Cr₹12926.27₹191.20+48.22%₹269.80
KRM Ayurveda Ltd.SME₹77.49 Cr₹13517.32₹180.70+33.85%₹299.30
Curis Lifesciences Ltd.SME₹27.52 Cr₹12812.44₹141.00+10.16%₹230.10
Aptus Pharma Ltd.SME₹13.02 Cr₹7011.29₹84.84+21.20%₹353.90
Symbiotec Pharmalab Ltd.Mainboard₹1,757.00 Cr₹98856.39₹1,097.70+11.10%₹1,055.75
Hexagon Nutrition Ltd.Mainboard₹138.87 Cr₹4522.69₹53.19+18.20%₹64.35
Sai Parenteral's Ltd.Mainboard₹408.79 Cr₹39272.19₹405.70+3.49%₹509.95
Corona Remedies Ltd.Mainboard₹655.37 Cr₹106243.47₹1,438.40+35.44%₹2,053.30
Rubicon Research Ltd.Mainboard₹1,377.50 Cr₹48555.75₹628.20+29.53%₹1,592.80

IPO Objects of the Issue

#Issue ObjectsEst Amt (₹ Cr.)
1Funding Working Capital Requirements13.75
2Business Development and Digital Marketing Activities7.50
3General Corporate Purposes3.17
4Issue Expenses2.08
Total26.50

Key Performance Indicator (KPI)

KPIMar 31, 2026
ROE63.87%
ROCE36.41%
Debt/Equity0.31
RoNW45.12%
PAT Margin17.16%
EBITDA Margin18.82%
NAV26.70
Price to Book Value3.97

IPO Valuation

Valuation MetricPre IPOPost IPO
EPS (₹)11.728.39
P/E (x)9.0412.63
Market Cap at Offer Price₹66.85 Cr.₹93.35 Cr

Shareholding Structure

CategoryPre IPOPost IPO
Promoter and Promoter Group95.14%68.13%
Public4.86%31.87%
Total100%100%

IPO Details

Review BySubscribeMay ApplyNeutralAvoid
Brokers0000
Members0000

IPO Subscription Status

CategorySubscription (x)Shares OfferedShares bid forTotal Applications
QIB (Ex Anchor)1.004,74,0004,74,0000
NII*3.583,56,40012,74,4000
bNII (> ₹10L)3.842,37,6009,13,200
sNII (< ₹10L)3.041,18,8003,61,200
Individual Investor2.568,32,80021,33,6000
Total2.3316,63,20038,82,0001,039

IPO Expenses

#Issue ExpensesEst Amt (₹ Cr.)
1Fees and commissions payable to the BRLM and Syndicate Member (including underwriting commission, brokerage and selling and marketing commission1.46
2Commission/processing fee for SCSBs, Sponsor Bank(s) and Banker to the Issue and fee payable to the Sponsor Bank for Bids made by RIBs, Brokerage, selling commission and bidding charges for Member of the Syndicate, Registered Brokers, CRTAs and CDP and Market Maker Fees0.09
3Fee payable to Legal Counsel0.09
4Fees to regulators, including Stock Exchange i.e. Listing fees, Exchange’s filing fees, upload fees, Exchange’s processing fees, book building software fees, fees payable to the Registrar to the Issue, postages, depository charges and other regulatory expenses0.11
5Printing and distribution of stationery0.01
6Advertising and marketing expenses0.13
7Miscellaneous0.19
Total2.08

Check Allotment Status

Allotment Out

Himalaya Nutravedics IPO — common questions

What is Himalaya Nutravedics IPO?

Himalaya Nutravedics IPO is a SME issue open from 22–24 September. The company is raising ₹26 Cr at a price band of ₹100 to ₹106 per share. One lot is 1,200 shares.

When does Himalaya Nutravedics IPO open and close?

The issue is open 22–24 September. Bids must be placed, and any UPI mandate approved, before the cut-off on the closing day.

What is the Himalaya Nutravedics IPO price band?

The price band is ₹100 to ₹106 per equity share, against a face value of ₹10. Retail investors may bid at cut-off, meaning they accept the final discovered price within this band.

What is the Himalaya Nutravedics IPO lot size?

The minimum application is 1,200 shares, and bids must be in multiples of that lot.

What is the Himalaya Nutravedics IPO issue size?

The total issue size is ₹26 Cr.

How is Himalaya Nutravedics IPO reserved between investor categories?

The issue is reserved as retail 33.32%, QIB 47.38%, HNI 14.26%. If the retail portion is oversubscribed, allotment there is decided by a lottery on lot-sized applications rather than in proportion to the amount applied for.

When is the Himalaya Nutravedics IPO allotment date?

Basis of allotment is expected to be finalised on 25 Sep 2026. You can check your status on the registrar's website (Kfin Technologies Ltd.) using your PAN.

When does Himalaya Nutravedics IPO list?

Listing is expected on 29 Sep 2026, following the T+3 timeline that applies to Indian IPOs.

Investment Disclaimer

This information is for educational purposes only. Please conduct your own research and consult with financial advisors before making investment decisions. IPO investments carry market risks.

Other IPOs to compare

Or see the full upcoming IPO list, today's grey market premium, subscription figures and allotment status.

Related IPO News & Insights

View All
Why 90% of Traders Lose Money in Option Trading
Risk Management

Why 90% of Traders Lose Money in Option Trading

Option trading me majority retail traders loss karte hain. Is guide me janiye beginners ki common mistakes, risk management strategies aur kaise disciplined trading se losses avoid kiye ja sakte hain.

10 Mar 2026
Read More
CMPDI IPO Coming Soon: Coal India Shareholders Ko Milega Special Quota
IPO News

CMPDI IPO Coming Soon: Coal India Shareholders Ko Milega Special Quota

CMPDI IPO soon launch ho sakta hai jisme 7.14 crore shares OFS ke through offer kiye jayenge. Coal India shareholders ko special quota mil sakta hai. Yaha CMPDI IPO ki complete details aur investment strategy janiye.

11 Mar 2026
Read More
Iran War Ka India Par Asar: Crude Oil ₹100, Rupee ₹92, Aur Share Market Crash — Aapko Kya Karna Chahiye?
News & Updates

Iran War Ka India Par Asar: Crude Oil ₹100, Rupee ₹92, Aur Share Market Crash — Aapko Kya Karna Chahiye?

US-Iran War ke baad se India mein crude oil $100 par, rupee record low ₹92 par, FPI ne ₹52,704 crore nikale, aur LPG sankat gahrata ja raha hai. Janiye is poori situation ka aapke investments par kya asar padega.

15 Mar 2026
Read More